This paper summarizes a pilot, sequential dose-escalation study of PEG-rHuMGDF in patients with advanced malignancies who had delayed platelet recovery after autologous stem cell transplantation (ASCT). Patients were randomized to receive either placebo (n = 11) or PEG-rHuMGDF at 5 (n = 9), 10 (n = 6), or 25 (n = 7) g/kg/day by subcutaneous injection for 14 days and were monitored for 5 weeks. Across all treatment groups, eight patients had platelet recovery to у20 × 10 9 /l by day 21. The proportion of patients achieving platelet recovery, the median number of days and units of platelet transfusions were similar for the placebo and the PEG-rHuMGDF groups. PEGrHuMGDF was well tolerated at all dosages. The incidence rates of adverse events in all groups were similar. No deaths on study, no drug-related serious adverse events, and no development of neutralizing antibodies to MGDF occurred. Bone Marrow Transplantation (2000) 26, 1083-1088. Keywords: PEG-rHuMGDF; platelet; engraftment; transplantation; clinical trial High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a commonly used therapeutic modality for a variety of solid and hematologic malignancies. ASCT has been associated with decreased treatment-related mortality over the last decade.
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a commonly used therapeutic modality for a variety of solid and hematologic malignancies. ASCT has been associated with decreased treatment-related mortality over the last decade. 1 However, in some situations delayed or failed reconstitution of white blood cells, red blood cells or platelets, despite stem cell infusion, can result in significant morbidity. A 1996 review suggested that delayed or nonengraftment of platelets occurs in a relatively large proportion of patients after highdose chemotherapy and ASCT. 2 In addition, platelet transfusions themselves can be a common source of complication, with untoward reactions reported in 13% to 38% of patients. 3, 4 The risk of allo-immunization, although Correspondence decreased with the use of leukofiltered products, still persists as a potential adverse outcome from platelet transfusions. A recent study reported that as many as 13% of patients with acute myelogenous leukemia (AML) developed HLA allo-antibodies and platelet transfusion refractoriness after red cell and platelet transfusions. 5 For these reasons, prolonged thrombocytopenia after ASCT remains a clinically important problem.
Thrombopoietin, also termed megakaryocyte growth and development factor (MGDF), is the ligand for the receptor c-Mpl and is the principal factor regulating platelet production. [6] [7] [8] [9] [10] Recombinant forms of the human Mpl ligand have been tested for biological activity, including the ability to stimulate the development of megakaryocytes from CD34 + progenitor cells in vitro, 6 increase the number and ploidy of megakaryocytes in vitro, 11, 12 and increase the peripheral platelet count in several animal models. [12] [13] [14] Pegylated (poly[ethylene]glycol-conjugated) recombinant human MGDF (PEG-rHuMGDF) is a modified, truncated form of thrombopoietin, produced in E. coli. PEG-rHuMGDF has been tested clinically in a wide range of indications. [15] [16] [17] We attempted to determine whether the addition of the exogenous Mpl ligand, PEG-rHuMGDF, would ameliorate thrombocytopenia of delayed platelet recovery in ASCT.
In this pilot study, we examined the safety and preliminary efficacy of PEG-rHuMGDF in patients with persistent, severe thrombocytopenia after high-dose chemotherapy and ASCT.
Patients and methods

Patients
The Institutional Review Boards of the participating centers approved the study protocol, and all patients gave written informed consent before entering the trial. Adults with a diagnosis of non-Hodgkin's lymphoma (NHL), Hodgkin's disease (HD), multiple myeloma, AML in remission before high-dose chemotherapy, or high-risk stage II, stage III, and stage IV breast cancer were eligible for inclusion in this study. All patients had undergone myeloablative chemotherapy supported by either autologous bone marrow transplantation (ABMT) or peripheral blood progenitor cell transplantation (PBPCT) and had not relapsed or experienced progression of disease. Eligibility criteria included a Karnofsky performance score of у60%, an absolute neutrophil count (ANC) у1 × 10 9 /l, and delayed platelet engraftment, defined as a transfusion-dependent platelet count Ͻ20 × 10 9 /l at least 28 days, but not more than 6 months, after ASCT. Normal cardiac, pulmonary, renal, and hepatic function was required. Patients were ineligible if they had a history of significant thrombotic events or significant cardiac disease, a diagnosis of hemolytic uremic syndrome or thrombotic thrombocytopenic purpura, or significant nonmalignant disease (including HIV infection). Patients could not be receiving warfarin, heparin, or ticlopidine hydrochloride, or have a known allergy to products derived from E. coli. Patients could not take aspirin or aspirin-containing products for the 7 days before randomization or at any time during the trial.
Study design
Potential patients were registered into the trial for full screening and within 7 days of planned randomization had a blood count to verify that they still met the eligibility criteria, including a platelet count Ͻ20 × 10 9 /l. Eligible patients were first stratified on the basis of type of stem cell graft and manipulation of the graft (PBSCT vs ABMT with tumor-cell purging vs ABMT without tumor cell purging). Patients were then randomly assigned in a 2:1 ratio to receive either PEG-rHuMGDF or placebo, respectively (minimum of nine per cohort) at one of three dosages (5, 10, and 25 g/kg/day). Study drug was started on day 1 (the day of randomization) and was administered subcutaneously (in a double-blind manner) once daily until a transfusion-independent platelet count у50 × 10 9 /l was achieved or for a maximum of 14 days. Each patient's status was assessed three times per week until day 35 to determine the efficacy and safety of the medication. The dosage of PEG-rHuMGDF was escalated to the next level after at least four patients in a single cohort had a satisfactory safety evaluation according to predefined rules.
Supportive care
Patients received platelet transfusions prophylactically if the platelet count decreased to Ͻ15 × 10 9 /l, or as clinically indicated. Filgrastim (r-metHuG-CSF) 5 g/kg/day was administered, if a patient's ANC was Ͻ0.5 × 10 9 /l. Packed red cell transfusions were given according to institutional standards.
Assessment of safety
Patients were examined for the occurrence of dose-limiting toxicity and other adverse events, changes in performance status, weight, or vital signs and changes in hematology and blood chemistry variables. Blood samples for determination of antibodies to MGDF were taken at baseline, after 4 weeks, and in the post-study follow-up period. The samples were analyzed using a standard solid-phase ELISA and, if reactive, a neutralizing antibody bioassay was used to evaluate the ability of the sera to inhibit the biological activity of TPO.
Assessment of efficacy
The primary efficacy endpoint was time to platelet recovery, defined as the number of days from randomization (day 1) to the second of 2 consecutive days of a platelet count у20 × 10 9 /l in the absence of platelet-transfusion support and with no subsequent platelet count Ͻ20 × 10 9 /l. Additional efficacy endpoints of platelet response included the proportion of patients achieving platelet recovery to у20 × 10 9 /l by day 21, the number of units of platelets transfused, and the days of platelet transfusions.
Statistical analysis
All patients who received at least one dose of PEGrHuMGDF or placebo were evaluable for the safety analysis. The primary analysis of efficacy was performed on an intent-to-treat basis. Results from inferential statistical analyses were assessed at the 0.05 level of significance (two-sided).
Point estimates and 95% confidence intervals were calculated for the proportion of patients who achieved platelet recovery to у20 × 10 9 /l by study days 21 and 35 in the placebo-and PEG-rHuMGDF-treatment groups. The distribution of platelet recovery times after the initiation of treatment with either PEG-rHuMGDF or placebo was estimated using the Kaplan-Meier method. The data for patients who did not achieve platelet recovery by study day 35 were censored on the day of their last platelet count measurement. An ordered comparison among the placebo and PEGrHuMGDF treatment groups was made using the trend version of the log-rank test as it was hypothesized that the time to platelet recovery would accelerate in a dose-related manner. The effects of prognostic variables and covariates on time to platelet recovery were assessed using Cox proportional hazards models.
Total units and days of platelet transfusions were summarized by calculating the mean, median, standard deviation, and range for patients in the placebo-and PEGrHuMGDF-treatment groups and were compared among these groups using the Jonckheere-Terpstra test.
Results
Patient characteristics and disposition
Forty-nine patients were registered for study screening, of whom 33 (22 females and 11 males) were randomized and, therefore, included in the intent-to-treat analysis of efficacy (Table 1) . Sixteen registered patients were not randomized either because their platelet count recovered, because they withdrew consent, or because they were otherwise ineligible.
The median age was 51 years (range, 21-69). Primary diagnoses included NHL, AML, multiple myeloma, breast cancer, and HD, in descending order of prevalence. Patients in this study had received a median of 10 cycles of prior PBPC transplant patients only. PBPCT = peripheral blood progenitor cell transplant; BMT = bone marrow transplant; PLT = platelet; NHL = non-Hodgkin's lymphoma; AML = acute myeloid leukemia.
chemotherapy (range, 3-36) for their primary malignancy. Additionally, 21 of the 33 patients had received prior radiation therapy. A variety of transplantation-conditioning regimens were used, but generally were high-dose combination chemotherapy (data not shown). Ten patients received total body irradiation as part of their conditioning regimen. Twentyfour patients were transplanted with PBPC alone, eight patients received bone marrow cells (two of whom had their cells purged), and one patient received PBPC combined with bone marrow. CD34
+ cell numbers were available only for those patients who had PBPCT and were measured according to individual institutional guidelines. As previously noted, the subjects were stratified by type of transplant, with the PBPC recipients evenly distributed among the treatment groups (Table 1) . Median CD34 + cell numbers were similar for those patients across all groups (range of median CD34 + cells number, 1.1 to 2.1 × 10 6 /kg). The highest median CD34 + cell counts were in the 10 g/kg/day group. The patient with the highest CD34 + cell yield was in the placebo group, and the patient with the lowest CD34 + cell yield was in the 5 g/kg/day group. For all patients, the median time from transplant to randomization was 49 days (range, 30-167), and the median platelet count at randomization was 11 × 10 9 /l (range, 3-18).
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Safety of PEG-rHuMGDF All 11 patients receiving placebo and 18 of 22 (82%) patients receiving PEG-rHuMGDF reported one or more adverse events. The reported events (eg neutropenia, nausea, and vomiting) were typical of those historically observed in patients who are profoundly myelosuppressed after aggressive therapy for advanced cancer. The incidence rates of adverse events observed in the PEG-rHuMGDFtreated groups were similar to those seen in the placebotreated group and no trends indicative of PEG-rHuMGDFrelated toxicity were evident. The only adverse events considered to be related to blinded study drug that were reported in more than one patient were injection-site ecchymosis (two placebo-treated patients), fatigue (two PEGrHuMGDF-treated patients), and ecchymosis, neutropenia, and rash (one placebo-treated and one PEG-rHuMGDFtreated patient, each).
Four patients experienced one or more hemorrhagic events during the study that required intervention with platelet transfusion(s): one patient who received PEGrHuMGDF 10 g/kg/day and three patients who received PEG-rHuMGDF 25 g/kg/day. These events, all of which were associated with profound thrombocytopenia, included gastrointestinal (GI) hemorrhage (five events), epistaxis (one event), and hematemesis (one event).
Days since initiation of PEG-rHuMGDF or placebo One thrombotic event was reported: access catheter clotting occurred in one patient treated with PEG-rHuMGDF 10 g/kg/day. No deaths on study, no drug-related serious adverse events, and no development of neutralizing antibodies to MGDF were detected.
No statistically or clinically significant trends were seen in vital signs, physical findings, or clinical laboratory values. No clinically significant infections were reported in any patient during the conduct of the study.
Efficacy assessments
Platelet recovery: Figure 1 shows the distribution of platelet recovery times to у20 × 10 9 /l after the initiation of PEG-rHuMGDF or placebo. Twelve patients (36%) overall achieved platelet recovery by study day 35, of which eight did so by study day 21 ( Table 2 ). The median time to recovery was 24 days for patients in the PEG-rHuMGDF 10 g/kg/day treatment group, and was not achieved in any other group. No dose-response trends were apparent, and no between-treatment group differences were observed (P = 0.6, log-rank trend test). Exploratory analysis indicated the elapsed time from transplant to the initiation of PEG-rHuMGDF or placebo was associated with the occurrence of platelet recovery (P = 0.04, chi-square test). The median duration between these events was 42 days (range, 30-72) for the 12 patients who achieved recovery. This compares with a median of 70 days (range, 30-167) for the remaining 21 patients whose platelet counts did not recover to у20 × 10 9 /l by study day 35. None of the other patient demographic and diseaserelated characteristics evaluated were associated with platelet recovery.
Platelet transfusions: Median number of days on which platelet transfusions were given and the median units of platelets transfused are shown in Figure 2 and Table 2 . There was no statistically significant difference in the number of transfusion days nor in the number of units transfused between placebo and the PEG-rHuMGDF treatment groups (P = 0.5, P = 0.6 respectively; JonckheereTerpstra test).
Discussion
This pilot study was designed primarily to assess the safety of PEG-rHuMGDF in a diverse patient population. Efficacy was a secondary endpoint, the results of which must be interpreted in the context of the small number of study subjects with heterogeneous cancers receiving a variety of conditioning and transplantation regimens. This study demonstrated, however, that PEG-rHuMGDF administered in dosages ranging from 5 to 25 g/kg/day for up to 14 days was well tolerated. No evidence of dose-related adverse effects, no differences in vital signs between patients receiving PEG-rHuMGDF or placebo, and no neutralizing antibodies were reported.
Although the study was not sufficiently powered to determine efficacy in this indication, we did evaluate the platelet response in these patients. Treatment-related effects of PEG-rHuMGDF on platelet recovery were not observed in this patient population. The proportion of patients showing platelet recovery by day 21 of treatment, days of platelet transfusions, and units of platelets transfused was similar in patients receiving PEG-rHuMGDF compared with patients receiving placebo.
There are several possible reasons for this lack of efficacy. Factors such as CD34 + cell yield, [18] [19] [20] the amount of chemotherapy and radiotherapy, 21 and the condition of the bone marrow at the time of transplantation all play a role in the persistence of thrombocytopenia in this setting. In this study, interpretation of the number of CD34 + cells varied according to institutional guidelines. Not all patients received optimal stem cell grafts and CD34 + cell numbers are not known for all patients. Intersite variability with respect to methodologies further complicates comparisons. However, the size and heterogeneity of the patient population limits the ability to perform multiple subset analyses in this study. The inability of exogenous Mpl ligand (PEGrHuMGDF) to significantly improve these patients' thrombocytopenia suggests that post-transplantation use for delayed platelet recovery should not be routine.
In summary, this study showed that PEG-rHuMGDF is safe up to 25 g/kg/day as administered, and that PEGrHuMGDF did not accelerate platelet recovery in the patients studied. Studies in selected subsets of patients or other schedules of administration may identify a more promising role for platelet growth factors for patients with Bone Marrow Transplantation persistent, severe thrombocytopenia after hematopoietic cell transplantation.
